File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.18632/oncotarget.4581
- Scopus: eid_2-s2.0-84944458774
- PMID: 26317793
- WOS: WOS:000363160100116
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Stemness And Chemotherapeutic Drug Resistance Induced By Eif5a2 Overexpression In Esophageal Squamous Cell Carcinoma
Title | Stemness And Chemotherapeutic Drug Resistance Induced By Eif5a2 Overexpression In Esophageal Squamous Cell Carcinoma |
---|---|
Authors | |
Keywords | chemoresistance EIF5A2 esophageal squamous cell carcinoma (ESCC) Stemness |
Issue Date | 2015 |
Publisher | Impact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html |
Citation | Oncotarget, 2015, v. 6 n. 28, p. 26079-26089 How to Cite? |
Abstract | Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies of the digestive tract in East Asian countries. Multimodal therapies, including adjuvant chemotherapy and neo-adjuvant chemotherapy, have become more often used for patients with advanced ESCC. However, the chemotherapy effect is often limited by patients' drug resistance. This study demonstrated that EIF5A2 (eukaryotic translation initiation factor 5A2) overexpression induced stemness and chemoresistance in ESCC cells. We showed that EIF5A2 overexpression in ESCC cells resulted in increased chemoresistance to 5-fluorouracil (5-FU), docetaxel and taxol. In contrast, shRNAs suppressing eIF5A2 increased tumor sensitivity to these chemotherapeutic drugs. In addition, EIF5A2 overexpression was correlated with a poorer overall survival in patients with ESCC who underwent taxane-based chemotherapy after esophagectomy (P > 0.05). Based on these results, we suggest that EIF5A2 could be a predictive biomarker for selecting appropriate chemo-treatment for ESCC patients and EIF5A2 inhibitors might be considered as combination therapy to enhance chemosensitivity in patients with ESCC. |
Persistent Identifier | http://hdl.handle.net/10722/222477 |
ISSN | 2016 Impact Factor: 5.168 2023 SCImago Journal Rankings: 0.789 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, H | - |
dc.contributor.author | Li, XD | - |
dc.contributor.author | Zhou, Y | - |
dc.contributor.author | Ban, X | - |
dc.contributor.author | Zeng, TT | - |
dc.contributor.author | Zhang, BZ | - |
dc.contributor.author | Yun, J | - |
dc.contributor.author | Xie, D | - |
dc.contributor.author | Guan, X | - |
dc.contributor.author | Li, Y | - |
dc.date.accessioned | 2016-01-18T07:41:06Z | - |
dc.date.available | 2016-01-18T07:41:06Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Oncotarget, 2015, v. 6 n. 28, p. 26079-26089 | - |
dc.identifier.issn | 1949-2553 | - |
dc.identifier.uri | http://hdl.handle.net/10722/222477 | - |
dc.description.abstract | Esophageal squamous cell carcinoma (ESCC) is one of the most lethal malignancies of the digestive tract in East Asian countries. Multimodal therapies, including adjuvant chemotherapy and neo-adjuvant chemotherapy, have become more often used for patients with advanced ESCC. However, the chemotherapy effect is often limited by patients' drug resistance. This study demonstrated that EIF5A2 (eukaryotic translation initiation factor 5A2) overexpression induced stemness and chemoresistance in ESCC cells. We showed that EIF5A2 overexpression in ESCC cells resulted in increased chemoresistance to 5-fluorouracil (5-FU), docetaxel and taxol. In contrast, shRNAs suppressing eIF5A2 increased tumor sensitivity to these chemotherapeutic drugs. In addition, EIF5A2 overexpression was correlated with a poorer overall survival in patients with ESCC who underwent taxane-based chemotherapy after esophagectomy (P > 0.05). Based on these results, we suggest that EIF5A2 could be a predictive biomarker for selecting appropriate chemo-treatment for ESCC patients and EIF5A2 inhibitors might be considered as combination therapy to enhance chemosensitivity in patients with ESCC. | - |
dc.language | eng | - |
dc.publisher | Impact Journals LLC. The Journal's web site is located at http://www.impactjournals.com/oncotarget/index.html | - |
dc.relation.ispartof | Oncotarget | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | chemoresistance | - |
dc.subject | EIF5A2 | - |
dc.subject | esophageal squamous cell carcinoma (ESCC) | - |
dc.subject | Stemness | - |
dc.title | Stemness And Chemotherapeutic Drug Resistance Induced By Eif5a2 Overexpression In Esophageal Squamous Cell Carcinoma | - |
dc.type | Article | - |
dc.identifier.email | Guan, X: xyguan@hkucc.hku.hk | - |
dc.identifier.authority | Guan, X=rp00454 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.18632/oncotarget.4581 | - |
dc.identifier.pmid | 26317793 | - |
dc.identifier.scopus | eid_2-s2.0-84944458774 | - |
dc.identifier.hkuros | 256785 | - |
dc.identifier.volume | 6 | - |
dc.identifier.issue | 28 | - |
dc.identifier.spage | 26079 | - |
dc.identifier.epage | 26089 | - |
dc.identifier.isi | WOS:000363160100116 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1949-2553 | - |